Novogen gets FDA orphan drug status for Anisina to treat neuroblastoma
The FDA granted orphan drug status for Anisina under the US Orphan Drug Act following a review by the agency of a package of pre-clinical data from preclinical
ProBio has entered into an exclusive worldwide licensing agreement with South Korean biotechnology firm AbTis to develop and commercialise an early-stage therapeutic antibody asset.
The open-label, single-arm, multicenter trial showed blinatumomab monotherapy induced a complete remission or complete remission with partial hematological recovery within two cycles of treatment in a clinically meaningful
The transaction provides Panther Biotechnology with a proprietary, multinational patent protected, ligand-drug conjugate technology platform as well as a pipeline of drug product candidates that address unmet medical